Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-848d4c4894-p2v8j Total loading time: 0.001 Render date: 2024-05-21T05:42:04.385Z Has data issue: false hasContentIssue false

Part II - Basic Ingredients for Adaptive Trial Designs and Common Types

Published online by Cambridge University Press:  20 March 2023

Jay J. H. Park ,
Edward J. Mills  and
J. Kyle Wathen
Jay J. H. Park
Affiliation:
McMaster University, Ontario
Edward J. Mills
Affiliation:
McMaster University, Ontario
J. Kyle Wathen
Affiliation:
Cytel, Cambridge, Massachusetts
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Introduction to Adaptive Trial Designs and Master Protocols , pp. 21 - 62
Publisher: Cambridge University Press
Print publication year: 2023

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

References

Dimairo, M, Pallmann, P, Wason, J, et al. The Adaptive Designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design. BMJ. 2020;369 :m115.Google Scholar
Dimairo, M, Pallmann, P, Wason, J, et al. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design. Trials. 2020;21(1):528.Google Scholar
Thorlund, K, Haggstrom, J, Park, JJ, Mills, EJ. Key design considerations for adaptive clinical trials: a primer for clinicians. BMJ. 2018;360:k698.Google Scholar
Pallmann, P, Bedding, AW, Choodari-Oskooei, B, et al. Adaptive designs in clinical trials: why use them, and how to run and report them. BMC Med. 2018;16(1):29.Google Scholar
ICH Harmonised Tripartite Guideline. Statistical principles for clinical trials. International Conference on Harmonisation E9 Expert Working Group. Stat Med. 1999;18(15):1905–42.Google Scholar
U.S. Food and Drug Administration. The Establishment and Operation of Clinical Trial Data Monitoring Committees for Clinical Trial Sponsors. United States Department of Health and Human Services; 2006.Google Scholar
Bhatt, DL, Mehta, C. Adaptive designs for clinical trials. N Engl J Med. 2016;375(1):65–74.CrossRefGoogle ScholarPubMed
Park, JJ, Thorlund, K, Mills, EJ. Critical concepts in adaptive clinical trials. Clin Epidemiol. 2018;10:343–51.Google Scholar
Fogel, DB. Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: a review. Contemp Clin Trials Commun. 2018;11:156–64.CrossRefGoogle ScholarPubMed
Tehranisa, JS, Meurer, WJ. Can response-adaptive randomization increase participation in acute stroke trials? Stroke. 2014;45(7):2131–3.Google Scholar
Florey, CD. Sample size for beginners. BMJ. 1993;306(6886):1181–4.Google Scholar
Hummel, J, Wang, S, Kirkpatrick, J. Using simulation to optimize adaptive trial designs: applications in learning and confirmatory phase trials. Clin Invest. 2015;5(4):401–13.Google Scholar
Detry, MA, Lewis, RJ, Broglio, KR, Standards for the design, conduct, and evaluation of adaptive randomized clinical trials. Patient-Centered Outcomes Research Institute (PCORI); 2012.Google Scholar
Sanchez-Kam, M, Gallo, P, Loewy, J, et al. A practical guide to data monitoring committees in adaptive trials. Ther Innov Regul Sci. 2014;48(3):316–26.Google Scholar
U.S. Food and Drug Administration. Adaptive Designs for Medical Device Clinical Studies Guidance for Industry and Food and Drug Administration Staff. United States Department of Health and Human Services; 2016.Google Scholar
United States Department of Health and Human Services, Food and Drug Administration. Adaptive Designs for Clinical Trials of Drugs and Biologics. Guidance for Industry. Center for Biologics Evaluation and Research (CBER); 2019.Google Scholar
Bauer, P, Bretz, F, Dragalin, V, Konig, F, Wassmer, G. Twenty-five years of confirmatory adaptive designs: opportunities and pitfalls. Stat Med. 2016;35(3):325–47.Google Scholar
Burton, A, Altman, DG, Royston, P, Holder, RL. The design of simulation studies in medical statistics. Stat Med. 2006;25(24):4279–92.CrossRefGoogle ScholarPubMed

References

Dimairo, M, Pallmann, P, Wason, J, et al. The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design. BMJ. 2020;369 :m115.Google ScholarPubMed
Dimairo, M, Pallmann, P, Wason, J, et al. The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design. Trials. 2020;21(1):528.Google Scholar
Thorlund, K, Haggstrom, J, Park, JJ, Mills, EJ. Key design considerations for adaptive clinical trials: a primer for clinicians. BMJ. 2018;360:k698.CrossRefGoogle ScholarPubMed
Park, JJ, Thorlund, K, Mills, EJ. Critical concepts in adaptive clinical trials. Clin Epidemiol. 2018;10:343–51.Google Scholar
Bhatt, DL, Mehta, C. Adaptive designs for clinical trials. N Engl J Med. 2016;375(1):65–74.Google Scholar
Pocock, SJ. Group sequential methods in the design and analysis of clinical trials. Biometrika. 1977;64(2):191–9.CrossRefGoogle Scholar
Bauer, P, Bretz, F, Dragalin, V, Konig, F, Wassmer, G. Twenty-five years of confirmatory adaptive designs: opportunities and pitfalls. Stat Med. 2016;35(3):325–47.CrossRefGoogle ScholarPubMed
Jennison, C, Turnbull, BW. Group Sequential Methods with Applications to Clinical Trials. Chapman and Hall/CRC; 1999.Google Scholar
Freidlin, B, Korn, EL. A comment on futility monitoring. Control Clin Trials. 2002;23(4):355–66.Google Scholar
Saville, BR, Connor, JT, Ayers, GD, Alvarez, J. The utility of Bayesian predictive probabilities for interim monitoring of clinical trials. Clin Trials. 2014;11(4):485–93.Google Scholar
Harari, O, Hsu, G, Dron, L, et al. Utilizing Bayesian predictive power in clinical trial design. Pharm Stat. 2020.Google Scholar
DeMets, DL, Pocock, SJ, Julian, DG. The agonising negative trend in monitoring of clinical trials. Lancet. 1999;354(9194):1983–8.Google Scholar
Ioannidis, JP, Evans, SJ, Gotzsche, PC, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med. 2004;141(10):781–8.CrossRefGoogle ScholarPubMed
Pocock, SJ. When to stop a clinical trial. BMJ. 1992;305(6847):235.Google Scholar
Armitage, P. Sequential medical trials: some comments on FJ Anscombe’s paper. JASA. 1963;58(302):384–7.Google Scholar
Armitage, P. Sequential Medical Trials. Wiley & Sons; 1975.Google Scholar
Fleming, TR, Harrington, DP, O’Brien, PC. Designs for group sequential tests. Control Clin Trials. 1984;5(4):348–61.Google Scholar
Pallmann, P, Bedding, AW, Choodari-Oskooei, B, et al. Adaptive designs in clinical trials: why use them, and how to run and report them. BMC Med. 2018;16(1):29.CrossRefGoogle Scholar
Berry, DA. Bayesian clinical trials. Nat Rev Drug Discov. 2006;5(1):27–36.Google Scholar
Kunzmann, K, Grayling, MJ, Lee, KM, et al. Conditional power and friends: the why and how of (un) planned, unblinded sample size recalculations in confirmatory trials. Stat Med. 2022;41(5):877–90.Google Scholar
Greenland, S, Senn, SJ, Rothman, KJ, et al. Statistical tests, P values, confidence intervals, and power: a guide to misinterpretations. Eur J Epidemiol. 2016;31(4):337–50.Google Scholar
Gordon Lan, K, Reboussin, DM, DeMets, DL. Information and information fractions for design and sequential monitoring of clinical trials. Commun Stat. 1994;23(2):403–20.Google Scholar
O’Brien, PC, Fleming, TR. A multiple testing procedure for clinical trials. Biometrics. 1979;35(3):549–56.Google Scholar
Haybittle, J. Repeated assessment of results in clinical trials of cancer treatment. Brit J Radiol. 1971;44(526):793–7.Google Scholar
Peto, R, Pike, M, Armitage, P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. BJC. 1976;34(6):585–612.Google Scholar
DeMets, DL, Lan, KG. Interim analysis: the alpha spending function approach. Stat Med. 1994;13(13‐14):1341–52.Google Scholar
Meurer, WJ, Tolles, J. Interim analyses during group sequential clinical trials. JAMA. 2021;326(15):1524–5.Google Scholar
Lan, GK, DeMets, DL. Discrete sequential boundaries for clinical trials. Biometrika. 1983;70(3):659–63.CrossRefGoogle Scholar
Kim, K, DeMets, DL. Design and analysis of group sequential tests based on the type I error spending rate function. Biometrika. 1987;74(1):149–54.Google Scholar
Davis, BR, Hardy, RJ. Data monitoring in clinical trials: the case for stochastic curtailment. J Clin Epidemiol. 1994;47(9):1033–42.CrossRefGoogle ScholarPubMed
Lakens, D, Pahlke, F, Wassmer, G. Group sequential designs: a tutorial. PsyArXiv Preprints. 2021.Google Scholar
Green, PJ, Łatuszyński, K, Pereyra, M, Robert, CP. Bayesian computation: a summary of the current state, and samples backwards and forwards. Stat Comput. 2015;25(4):835–62.CrossRefGoogle Scholar
Spiegelhalter, DJ, Freedman, LS, Blackburn, PR. Monitoring clinical trials: conditional or predictive power? Control Clin Trials. 1986;7(1):8–17.Google Scholar
Park, JW, Liu, MC, Yee, D, et al. Adaptive randomization of neratinib in early breast cancer. N Engl J Med. 2016;375(1):11–22.Google Scholar
Rugo, HS, Olopade, OI, DeMichele, A, et al. Adaptive randomization of veliparib-carboplatin treatment in breast cancer. N Engl J Med. 2016;375(1):23–34.CrossRefGoogle ScholarPubMed
Viele, K, McGlothlin, A, Broglio, K. Interpretation of clinical trials that stopped early. JAMA. 2016;315(15):1646–7.CrossRefGoogle ScholarPubMed
Goodman, SN. Stopping at Nothing? Some Dilemmas of Data Monitoring in Clinical Trials, pp. 882–7. American College of Physicians; 2007.Google Scholar
Florey, CD. Sample size for beginners. BMJ. 1993;306(6886):1181–4.Google Scholar
Bauer, P, Koenig, F. The reassessment of trial perspectives from interim data – a critical view. Stat Med. 2006;25(1):23–36.Google Scholar
Posch, M, Klinglmueller, F, Konig, F, Miller, F. Estimation after blinded sample size reassessment. Stat Methods Med Res. 2018;27(6):1830–46.Google Scholar
Brannath, W, Mehta, CR, Posch, M. Exact confidence bounds following adaptive group sequential tests. Biometrics. 2009;65(2):539–46.Google Scholar
Kieser, M, Friede, T. Simple procedures for blinded sample size adjustment that do not affect the type I error rate. Stat Med. 2003;22(23):3571–81.Google Scholar
Lin, J, Lin L-A, , Sankoh, S. A general overview of adaptive randomization design for clinical trials. J Biom Biostat. 2016;7(2):294.Google Scholar
Lin, Y, Zhu, M, Su, Z. The pursuit of balance: an overview of covariate-adaptive randomization techniques in clinical trials. Contemp Clin Trials. 2015;45(Pt A):21–5.Google Scholar
Atkinson, AC, Biswas, A. Randomised Response-Adaptive Designs in Clinical Trials. CRC Press; 2013.Google Scholar
Taves, DR. Minimization: a new method of assigning patients to treatment and control groups. Clin Pharmacol Ther. 1974;15(5):443–53.Google Scholar
Pocock, SJ, Simon, R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics. 1975;31(1):103–15.CrossRefGoogle ScholarPubMed
Altman, DG, Bland, JM. Treatment allocation by minimisation. BMJ. 2005;330(7495):843.Google Scholar
Zajicek, J, Ball, S, Wright, D, et al. Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial. Lancet Neurol. 2013;12(9):857–65.Google Scholar
Treasure, T, MacRae, KD. Minimisation: the platinum standard for trials? Randomisation doesn’t guarantee similarity of groups; minimisation does.BMJ. 1998;317(7155):362–3.Google Scholar
Rosenberger, WF, Lachin, JM. Randomization in Clinical Trials: Theory and Practice. Wiley & Sons; 2015.Google Scholar
Saghaei, M. An overview of randomization and minimization programs for randomized clinical trials. J Med Signals Sens. 2011;1(1):55–61.Google Scholar
Angus, DC. Optimizing the trade-off between learning and doing in a pandemic. JAMA. 2020;323(19):1895–6.CrossRefGoogle ScholarPubMed
Creel, AH, Losina, E, Mandl, LA, et al. An assessment of willingness to participate in a randomized trial of arthroscopic knee surgery in patients with osteoarthritis. Contemp Clin Trials. 2005;26(2):169–78.CrossRefGoogle Scholar
Proschan, M, Evans, S. Resist the temptation of response-adaptive randomization. Clin Infect Dis. 2020;71(11):3002–4.Google Scholar
Viele, K, Broglio, K, McGlothlin, A, Saville, BR. Comparison of methods for control allocation in multiple arm studies using response adaptive randomization. Clin Trials. 2020;17(1):52–60.Google Scholar
Thall, P, Fox, P, Wathen, J. Statistical controversies in clinical research: scientific and ethical problems with adaptive randomization in comparative clinical trials. Ann Oncol. 2015;26(8):1621–8.Google Scholar
Wathen, JK, Thall, PF. A simulation study of outcome adaptive randomization in multi-arm clinical trials. Clin Trials. 2017;14(5):432–40.Google Scholar
London, AJ. Learning health systems, clinical equipoise and the ethics of response adaptive randomisation. J Med Ethics. 2018;44(6):409–15.Google Scholar
Meurer, WJ, Lewis, RJ, Berry, DA. Adaptive clinical trials: a partial remedy for the therapeutic misconception? JAMA. 2012;307(22):2377–8.Google Scholar
Tehranisa, JS, Meurer, WJ. Can response-adaptive randomization increase participation in acute stroke trials? Stroke. 2014;45(7):2131–3.Google Scholar
Thompson, WR. On the likelihood that one unknown probability exceeds another in view of the evidence of two samples. Biometrika. 1933;25(3-4):285–94.Google Scholar
Juszczak, E, Altman, DG, Hopewell, S, Schulz, K. Reporting of multi-arm parallel-group randomized trials: extension of the consort 2010 statement. JAMA. 2019;321(16):1610–20.Google Scholar
Koenig, F, Brannath, W, Bretz, F, Posch, M. Adaptive Dunnett tests for treatment selection. Stat Med. 2008;27(10):1612–25.Google Scholar
Zhao, W, Durkalski, V. Managing competing demands in the implementation of response‐adaptive randomization in a large multicenter phase III acute stroke trial. Stat Med 2014;33(23):4043–52.Google Scholar
Treweek, S, Pitkethly, M, Cook, J, et al. Strategies to improve recruitment to randomised trials. Cochrane Database Syst Rev. 2018;2:MR000013.Google Scholar
Hodson, R. Precision oncology. Nature. 2020;585(7826):S1.Google Scholar
Simon, N, Simon, R. Adaptive enrichment designs for clinical trials. Biostatistics. 2013;14(4):613–25.CrossRefGoogle ScholarPubMed
Antoniou, M, Jorgensen, AL, Kolamunnage-Dona, R. Biomarker-guided adaptive trial designs in phase II and phase III: a methodological review. PLoS One. 2016;11(2):e0149803.Google Scholar
Antoniou, M, Kolamunnage-Dona, R, Jorgensen, AL. Biomarker-guided non-adaptive trial designs in phase II and phase III: a methodological review. J Pers Med. 2017;7(1).Google Scholar
Mehta, CR, Gao, P. Population enrichment designs: case study of a large multinational trial. J Biopharm Stat. 2011;21(4):831–45.Google Scholar
Nogueira, RG, Jadhav, AP, Haussen, DC, et al. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. N Engl J Med. 2018;378(1):11–21.CrossRefGoogle ScholarPubMed
Antoniou, M, Kolamunnage-Dona, R, Wason, J, et al. Biomarker-guided trials: Challenges in practice. Contemp Clin Trials Commun. 2019;16:100493.Google Scholar
Grudzinskas, C. Design of clinical development programs. In Atkinson, AJ, Abernethy, DR, Daniels, CE, Dedrick, RL, Markey, SP, editors. Principles of Clinical Pharmacology, 2nd ed., pp. 501–17. Academic Press; 2007.Google Scholar
Cuffe, RL, Lawrence, D, Stone, A, Vandemeulebroecke, M. When is a seamless study desirable? Case studies from different pharmaceutical sponsors. Pharmaceutical statistics. 2014;13(4):229–37.Google Scholar
Hobbs, BP, Barata, PC, Kanjanapan, Y, et al. Seamless designs: current practice and considerations for early-phase drug development in oncology. J Natl Cancer Inst. 2019;111(2):118–28.Google Scholar
Sydes, MR, Parmar, MK, Mason, MD, et al. Flexible trial design in practice – stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial. Trials. 2012;13:168.Google Scholar
Barker, AD, Sigman, CC, Kelloff, GJ, et al. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther. 2009;86(1):97–100.Google Scholar

References

Gasparini, A, Morris, TP, Crowther, MJ. INTEREST: INteractive Tool for Exploring REsults from Simulation sTudies. J Data Sci Stat Vis. 2021;1(4).Google ScholarPubMed
Burton, A, Altman, DG, Royston, P, Holder, RL. The design of simulation studies in medical statistics. Stat Med. 2006;25(24):4279–92.Google Scholar
Boulesteix, AL, Groenwold, RH, Abrahamowicz, M, et al. Introduction to statistical simulations in health research. BMJ Open. 2020;10(12):e039921.Google Scholar
Mayer, C, Perevozskaya, I, Leonov, S, et al. Simulation practices for adaptive trial designs in drug and device development. Stat Biopharm Res. 2019;11(4):325–35.Google Scholar
United States Department of Health and Human Services, Food and Drug Administration. Adaptive Designs for Clinical Trials of Drugs and Biologics. Guidance for Industry. Center for Biologics Evaluation and Research (CBER); 2019.Google Scholar
U.S. Food and Drug Administration. Adaptive Designs for Medical Device Clinical Studies Guidance for Industry and Food and Drug Administration Staff. United States Department of Health and Human Services; 2016.Google Scholar
Hummel, J, Wang, S, Kirkpatrick, J. Using simulation to optimize adaptive trial designs: applications in learning and confirmatory phase trials. Clin Investig. 2015;5(4):401–13.CrossRefGoogle Scholar
Gaydos, B, Anderson, KM, Berry, D, et al. Good practices for adaptive clinical trials in pharmaceutical product development. Drug Inf J. 2009;43(5):539–56.CrossRefGoogle Scholar
Thorlund, K, Golchi, S, Haggstrom, J, Mills, E. Highly Efficient Clinical Trials Simulator (HECT): software application for planning and simulating platform adaptive trials. Gates Open Res. 2019;3:780.CrossRefGoogle ScholarPubMed
Thorlund, K, Haggstrom, J, Park, JJ, Mills, EJ. Key design considerations for adaptive clinical trials: a primer for clinicians. BMJ. 2018;360:k698.Google Scholar
Wason, JM, Brocklehurst, P, Yap, C. When to keep it simple–adaptive designs are not always useful. BMC Med. 2019;17(1):1–7.Google Scholar
Thall, P, Fox, P, Wathen, J. Statistical controversies in clinical research: scientific and ethical problems with adaptive randomization in comparative clinical trials. Ann Oncol. 2015;26(8):1621–8.Google Scholar
Meyer, EL, Mesenbrink, P, Mielke, T, et al. Systematic review of available software for multi-arm multi-stage and platform clinical trial design. Trials. 2021;22(1):183.Google Scholar
Weston, SJ, Yee, D. Why you should become a useR: a brief introduction to R. APS Obs. 2017;30(3).Google Scholar
Grayling, MJ, Wason, JM. A web application for the design of multi-arm clinical trials. BMC Cancer. 2020;20(1):80.Google Scholar
Wassmer, G, Pahlke, F. Rpact: confirmatory adaptive clinical trial design and analysis. R package version; 2021.Google Scholar
Kunzmann, K, Pilz, M, Herrmann, C, Rauch, G, Kieser, M. The adoptr package: adaptive optimal designs for clinical trials in R. J Stat Softw. 2021;98:1–21.Google Scholar
Granholm, A, Jensen, AKG, Lange, T, Kaas-Hansen, BS. adaptr: an R package for simulating and comparing adaptive clinical trials. J Open Source Softw. 2022;7(72):4284.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×